Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA

Kidney International

Volumn 63, Issue 1, 2003, Pages 96-106

  Choi, Mira ^a,b,c   Rolle, Susanne ^a,b,c   Rane, Madhavi ^a,b,c   Haller, Hermann ^a,b,c   Luft, Friedrich C ^a,b,c   Kettritz, Ralph ^a,b,c,d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d FRANZ VOLHARD CLINIC   (Germany)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A; Anti neutrophil cytoplasmic antibodies; Mitogen activated protein kinases; Neutrophils; Respiratory burst; Signal transduction; Superoxide

Indexed keywords

CERIVASTATIN; CYTOCHROME C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NITROBLUE TETRAZOLIUM; SIMVASTATIN; SUPEROXIDE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY ISOLATION; ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVITY; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; NEUTROPHIL; NORMAL HUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RESPIRATORY BURST; WESTERN BLOTTING;

EID: 0037213448     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00718.x     Document Type: Article

References (36)

1. Van der Woude FJ, Rasmussen N, Lobatto S, et al: Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker for disease activity in Wegener's granulomatosis. Lancet i:425-429, 1985
2. Jennette JC, Falk RJ: Small-vessel vasculitis. N Engl J Med 337: 1512-1523, 1997
3. Franssen CF, Huitema MG, Muller Kobold AC, et al: In vitro neutrophil activation by antibodies to proteinase 3 and myeloperoxidase from patients with crescentic glomerulonephritis. J Am Soc Nephrol 10:1506-1515, 1999
4. Falk RJ, Terrell RS, Charles LA, et al: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119, 1990
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
6. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344:633-638, 1994
7. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97:1440-1445, 1998
8. Downs JR, Clearfield M, Weis S, et al: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622, 1998
9. Horne BD, Muhlestein JB, Carlquist JF, et al: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 36:1774-1780, 2000
10. Ikeda U, Ito T, Shimada K: Statins and C-reactive protein. Lancet 353:1274-1275, 1999
11. Strandberg TE, Vanhanen H, Tikkanen MJ: Associations between change in C-reactive protein and serum lipids during statin treatment. Ann Med 32:579-583, 2000
12. Park JK, Muller DN, Mervaala EM, et al: Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure-and cholesterol-lowering effects. Kidney Int 58:1420-1430, 2000
13. Dunzendorfer S, Rothbucher D, Schratzberger P, et al: Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin. Circ Res 81:963-969, 1997
14. Kanno T, Abe K, Yabuki M, et al: Selective inhibition of formyl-methionyl-leucyl-phenylalanine (fMLF)-dependent superoxide generation in neutrophils by pravastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Biochem Pharmacol 58:1975-1980, 1999
15. Stegeman CA, Tervaert JW, Sluiter WJ, et al: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 120:12-17, 1994
16. Kallenberg CG, Brouwer E, Mulder AH, et al: ANCA-pathophysiology revisited. Clin Exp Immunol 100:1-3, 1995
17. Stegeman CA, Cohen Tervaert JW, De Jong PE, Kallenberg CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16-20, 1996
18. Pick E, Mizel D: Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods 46:211-226, 1981
19. Kettritz R, Jennette JC, Falk RJ: Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 8:386-394, 1997
20. Kettritz R, Schreiber A, Luft FC, Haller H: Role of mitogen-activated protein kinases in activation of human neutrophils by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 12:37-46, 2001
21. Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365-376, 1989
22. Kothe H, Dalhoff K, Rupp J, et al: Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 101:1760-1763, 2000
23. Koga T, Fukuda K, Shimada Y, et al: Tissue selectivity of pravastatin sodium, lovastatin and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 209:315-319, 1992
24. Bischoff H, Angerbauer R, Boberg M, et al: Preclinical review of cerivastatin sodium-A step forward in HMG-CoA reductase inhibition. Atherosclerosis 139(Suppl 1):S7-S13, 1998
25. Boberg M, Angerbauer R, Kanhai WK, et al: Biotransformation of cerivastatin in mice, rats, and dogs in vivo. Drug Metab Dispos 26:640-652, 1998
26. Kreuzer J, Bader J, Jahn L, et al: Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 90:203-209, 1991
27. Yachnin S, Toub DB, Mannickarottu V: Divergence in cholesterol biosynthetic rates and 3-hydroxy-3-methylglutaryl-CoA reductase activity as a consequence of granulocyte versus monocyte-macrophage differentiation in HL-60 cells. Proc Natl Acad Sci USA 81:894-897, 1984
28. Chen L, Haught WH, Yang B, et al: Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol 30:569-575, 1997
29. Girona J, La Ville AE, Sola R, et al: Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83:846-851, 1999
30. Laufs U, Marra D, Node K, Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274:21926-21931, 1999
31. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S: Involvement of Rho GTPases in the transcriptional inhibition of prepro-endothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 87:616-622, 2000
32. Satoh K, Ichihara K, Landon EJ, et al: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors block calcium-dependent tyrosine kinase Pyk2 activation by angiotensin II in vascular endothelial cells. Involvement of geranylgeranylation of small G protein Rap1. J Biol Chem 276:15761-15767, 2001
33. Mehta JL, Li DY, Chen HJ, et al: Inhibition of LOX-1 by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 289:857-861, 2001
34. Yokota T, Utsunomiya K, Murakawa Y, et al: Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy. Kidney Int 56(Suppl 71):S178-S181, 1999
35. Bassa BV, Roh DD, Vaziri ND, et al: Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Biochim Biophys Acta 1449:137-149, 1999
36. Goldman F, Hohl RJ, Crabtree J, et al: Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 88:4611-4619, 1996